Also found in: Dictionary.


(zi-pra-si-done) ,


(trade name),


(trade name)


Therapeutic: antipsychotics
Pharmacologic: piperazine derivatives
Pregnancy Category: C


Schizophrenia; IM form is reserved for control of acutely agitated patients.Treatment of acute manic or mixed episodes associated with Bipolar I Disorder (oral only).Maintenance treatment of Bipolar I Disorder (as adjunct to lithium or valproate) (oral only).


Effects probably mediated by antagonism of dopamine type 2 (D2) and serotonin type 2 (5-HT2). Also antagonizes α2 adrenergic receptors.

Therapeutic effects

Diminished schizophrenic behavior.


Absorption: 60% absorbed following oral administration; 100% absorbed from IM sites.
Distribution: Unknown.
Protein Binding: 99%; potential for drug interactions due to drug displacement is minimal.
Metabolism and Excretion: 99% metabolized by the liver; <1% excreted unchanged in urine.
Half-life: PO—7 hr; IM—2–5 hr.

Time/action profile (blood levels)

POwithin hours1–3 days†unknown
IMrapid60 minunknown
†Steady state achieved following continuous use


Contraindicated in: Hypersensitivity;History of QT prolongation (persistent QTc measurements >500 msec), arrhythmias, recent MI or uncompensated heart failure;Concurrent use of other drugs known to prolong the QT interval including quinidine, dofetilide, sotalol, other class Ia and III antiarrhythmics, pimozide, sotalol, thioridazine, chlorpromazine, pentamidine, arsenic trioxide, mefloquine, dolasetron, tacrolimus, droperidol, and moxifloxacin;Hypokalemia or hypomagnesemia; Lactation: Discontinue drug or bottle feed.
Use Cautiously in: Concurrent diuretic therapy or diarrhea (may ↑ the risk of hypotension, hypokalemia, or hypomagnesemia);Significant hepatic impairment;History of cardiovascular or cerebrovascular disease;Hypotension, concurrent antihypertensive therapy, dehydration, or hypovolemia (may ↑ risk of orthostatic hypotension); Obstetric: Neonates at ↑ risk for extrapyramidal symptoms and withdrawal after delivery when exposed during the 3rd trimester; use only if maternal benefit outweighs risk to fetus; Pediatric: Safety not established; Geriatric: Alzheimer's dementia or age >65 yr (may ↑ risk of seizures). Geriatric patients (may require ↓ doses; ↑ risk of mortality in elderly patients treated for dementia-related psychosis);Patients at risk for aspiration pneumonia;History of suicide attempt.

Adverse Reactions/Side Effects

Central nervous system

  • neuroleptic malignant syndrome (life-threatening)
  • seizures
  • dizziness (most frequent)
  • drowsiness (most frequent)
  • restlessness (most frequent)
  • extrapyramidal reactions
  • syncope
  • tardive dyskinesia


  • cough/runny nose


  • prolonged qt interval (life-threatening)
  • orthostatic hypotension


  • constipation (most frequent)
  • diarrhea (most frequent)
  • nausea (most frequent)
  • dysphagia


  • amenorrhea
  • impotence


  • agranulocytosis (life-threatening)
  • leukopenia
  • neutropenia


  • galactorrhea
  • hyperglycemia
  • hyperlipidemia
  • weight gain


  • rash
  • urticaria


Drug-Drug interaction

Concurrent use of quinidine, dofetilide, other class Ia and III antiarrhythmics, pimozide, sotalol, thioridazine, chlorpromazine, pentamidine, arsenic trioxide, mefloquine, dolasetron, tacrolimus, droperidol, moxifloxacin, or other agents that prolong the QT interval may result in potentially life-threatening adverse drug reactions (concurrent use contraindicated).Additive CNS depression may occur with alcohol, antidepressants, antihistamines, opioid analgesics, or sedative/hypnotics.Blood levels and effectiveness may be ↓ by carbamazepine.Blood levels and effects may be ↑ by ketoconazole.



Oral (Adults) 20 mg twice daily initially; dose increments may be made at 2-day intervals up to 80 mg twice daily.
Intramuscular (Adults) 10–20 mg as needed up to 40 mg/day; may be given as 10 mg every 2 hr or 20 mg every 4 hr.

Acute Manic or Mixed Episodes Associated with Bipolar I Disorder

Oral (Adults) 40 mg twice on first day, then 60 or 80 mg twice daily on second day, then 40–80 mg twice daily.

Maintenance Treatment of Bipolar I Disorder (as adjunct to lithium or valproate)

Oral (Adults) Continue same dose on which patient was initially stabilized (range: 40–80 mg twice daily).

Availability (generic available)

Capsules: 20 mg, 40 mg, 60 mg, 80 mg Cost: Generic — 20 mg $380.02 / 180, 40 mg $544.16 / 180, 60 mg $451.99 / 180, 80 mg $451.99 / 180
Lyophilized powder for injection (requires reconstitution): 20 mg/vial

Nursing implications

Nursing assessment

  • Monitor patient’s mental status (orientation, mood, behavior) prior to and periodically during therapy.
  • Assess weight and BMI initially and periodically during therapy.
  • Monitor BP (sitting, standing, lying) and pulse rate prior to and frequently during initial dose titration. Patients found to have persistent QTc measurements of >500 msec should have ziprasidone discontinued. Patients who experience dizziness, palpitations, or syncope may require further evaluation (i.e., Holter monitoring).
  • Assess for rash during therapy. May be treated with antihistamines or corticosteroids. Usually resolves upon discontinuation of ziprasidone. Medication should be discontinued if no alternative etiology for rash is found.
  • Observe carefully when administering medication to ensure medication is actually taken and not hoarded or cheeked.
  • Monitor for onset of akathisia (restlessness or desire to keep moving) and extrapyramidal side effects (parkinsonian—difficulty speaking or swallowing, loss of balance control, pill rolling of hands, mask-like face, shuffling gait, rigidity, tremors and dystonic muscle spasms, twisting motions, twitching, inability to move eyes, weakness of arms or legs) every 2 mo during therapy and 8–12 wk after therapy has been discontinued. Notify health care professional if these symptoms occur, as reduction in dose or discontinuation of medication may be necessary. Trihexyphenidyl or benztropine may be used to control these symptoms.
  • Although not yet reported for ziprasidone, monitor for possible tardive dyskinesia (uncontrolled rhythmic movement of mouth, face, and extremities, lip smacking or puckering, puffing of cheeks, uncontrolled chewing, rapid or worm-like movements of tongue). Report these symptoms immediately; may be irreversible.
  • Monitor frequency and consistency of bowel movements. Increasing bulk and fluids in the diet may help to minimize constipation.
  • Ziprasidone lowers the seizure threshold. Institute seizure precautions for patients with history of seizure disorder.
  • Monitor for development of neuroleptic malignant syndrome (fever, respiratory distress, tachycardia, seizures, diaphoresis, hypertension or hypotension, pallor, tiredness). Notify health care professional immediately if these symptoms occur.
  • Monitor for symptoms related to hyperprolactinemia (menstrual abnormalities, galactorrhea, sexual dysfunction).
  • Lab Test Considerations: Monitor serum potassium and magnesium prior to and periodically during therapy. Patients with low potassium or magnesium should have levels treated and checked prior to resuming therapy. Obtain fasting blood glucose and cholesterol levels initially and periodically during therapy.
    • Monitor CBC frequently during initial months of therapy in patients with pre-existing or history of low WBC. May cause leukopenia, neutropenia, or agranulocytosis. Discontinue therapy if this occurs.
    • Monitor serum prolactin prior to and periodically during therapy. May cause ↑ serum prolactin levels.

Potential Nursing Diagnoses

Risk for other-directed violence (Indications)
Disturbed thought process (Indications)
Imbalanced nutrition: risk for more than body requirements (Side Effects)


  • Dose adjustments should be made at intervals of no less than 2 days. Usually patients should be observed for several weeks before dose titration.
    • Patients on parenteral therapy should be converted to oral doses as soon as possible.
  • Oral: Administer capsules with food or milk to decrease gastric irritation. Swallow capsules whole; do not open.
  • Intramuscular: Add 1.2 mL of Sterile Water for Injection to the vial; shake vigorously until all drug is dissolved for a concentration of 20 mg/mL. Discard unused portion. Do not mix with other products or solutions. Do not administer solutions that are discolored or contain particulate matter.

Patient/Family Teaching

  • Instruct patient to take medication as directed, at the same time each day. Do not discontinue medication without discussing with health care professional, even if feeling well. Patients on long-term therapy may need to discontinue gradually.
  • Inform patient of possibility of extrapyramidal symptoms. Instruct patient to report these symptoms immediately.
  • Advise patient to change positions slowly to minimize orthostatic hypotension.
  • May cause seizures and drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications. Caution patient to avoid concurrent use of alcohol and other CNS depressants.
  • Advise patient to notify health care professional of medication regimen prior to treatment or surgery.
  • Instruct patient to notify health care professional promptly if dizziness, loss of consciousness, palpitations, menstrual abnormalities, galactorrhea or sexual dysfunction occur.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected, or if breast feeding or planning to breast feed.
  • Advise patient of need for continued medical follow-up for psychotherapy, eye exams, and laboratory tests.

Evaluation/Desired Outcomes

  • Decrease in acute excited, manic behavior.
  • Decrease in positive (delusions, hallucinations) and negative symptoms (social withdrawal, flat, blunted affect) of schizophrenia.
  • Management of signs and symptoms of Bipolar I Disorder.


Ziprasidone Psychiatry A neuropharmacologic used for schizophrenia and to prevent psychotic relapses. See Schizophrenia.
Mentioned in ?
References in periodicals archive ?
Closest to market are Relpax, for acute migraine; Zeldox, an antipsychotic; Vfend, an antifungal; Valdecoxib, the next generation of Celebrex; Pregabalin, for pain; Exubera, an inhaled insulin; and Capravirine, for AIDs.
In a surprising setback for one of its new products, the FDA recently rejected its antipsychotic drug Zeldox, setting back the product launch, which was originally scheduled for the last quarter of this year.
1 Table of contents 2 Introduction 3 Schizophrenia: Market Characterization 4 Classification of Schizophrenia 5 Treatment for Schizophrenia 6 Geodon/ Zeldox 7 Schizophrenia Market: Appendix